Skip to main content
Premium Trial:

Request an Annual Quote

Maven Bio Seeks Buyer for Label-Free Detection, Imaging Technology

NEW YORK (GenomeWeb News) – Maven Biotechnologies is seeking a buyer for its label-free detection and imaging technology.

The technology called LFIRE is a method for detection and ellipsometry reflection and provides enhanced, high-content, label-free detection and imaging and high-capacity screening. Today, BioMed Transition Partners announced Maven Bio has retained its services to help find a buyer for the technology.

Monrovia, Calif.-based life science tools company Maven Bio said on its website that LFIRE measures biomolecular interactions in a microarray or well-plate format, and added that as a real-time system, it provides information about a sample before and after equilibrium, which is required "for increasing the dynamic range of concentration measurements, optimizing biological assays, and analyzing kinetic activity critical to drug research."

The system, which can be used for molecular and cell-based assays, is currently in the optimization stage of development and is near market commercialization for research applications, BioMed Transition said.

The technology has applications in research, development, and quality control in academic laboratories, pharmaceutical companies, clinical diagnostics, point-of-care diagnostics, and the animal health and food and beverage markets, the New York-based biomedical management advisory firm added. BioMed Transition is an affiliate of The Channel Group, an investment, development, and management firm.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.